The work described here builds on a large body of work on functional assays on cancer predisposition genes such as TP53, BRCA1, BRCA2 and MSH236–40 and supports the notion that despite limitations the use of functional assay data is likely to contribute to assessment of an increasingly larger share of VUS and provide more accurate integrated risk models to achieve better clinical outcomes. This evidence concerns the gene BRCA2 and cancer.